Almoxatone

Almoxatone

Almoxatone is a monoamine oxidase inhibitor (MAOI) that was developed in the 1980s for the treatment of depression. It was never marketed, but has been used in scientific research to study the monoamine oxidase (MAO) enzyme and its role in depression.

History

Almoxatone was developed in the 1980s by the pharmaceutical company Upjohn. It was one of several MAOIs developed during this time period, as researchers were seeking more effective and safer treatments for depression. Despite showing promise in early trials, Almoxatone was never marketed.

Pharmacology

Almoxatone is a selective inhibitor of the monoamine oxidase A (MAO-A) enzyme. This enzyme is responsible for breaking down several important neurotransmitters in the brain, including serotonin, norepinephrine, and dopamine. By inhibiting this enzyme, Almoxatone increases the levels of these neurotransmitters in the brain, which can help to alleviate the symptoms of depression.

Research

Although Almoxatone was never marketed as a treatment for depression, it has been used in scientific research to study the MAO-A enzyme and its role in depression. Research has shown that people with depression often have higher levels of MAO-A in their brains, and that inhibiting this enzyme can help to alleviate depressive symptoms.

See also

• Monoamine oxidase inhibitor
• Depression
• Monoamine oxidase A
• Serotonin
• Norepinephrine
• Dopamine